Igniting patient activation in Europe: What pharma can do now
Pricing pressure is on the rise. Portfolios are shifting toward complex treatment journeys and precision therapies. What should pharma do now? As detailed in the 2026 Future of Health Report, it’s time to embrace patient centricity and recognize patients are a core stakeholder in go-to-market strategies.
But addressing the treatment barriers that prevent patients from moving forward in care journeys takes more than building awareness. We have to help patients seek care, navigate the system and advocate for the right treatments. That shift matters most in rare and specialty conditions, where the diagnostic journey is longest—but the logic applies to any asset whose patients are hard to find and harder to route.
As traditional commercial models face growing pressure across Europe, pharma has an opportunity to play a more active role in helping patients access timely diagnosis and treatment. This white paper examines why patient activation is emerging as a critical growth lever in European markets and how companies can work through trusted local ecosystems—including pharmacies, digital health platforms and virtual care—to move patients toward appropriate care.
Drawing on real-world case studies and a practical roadmap for action, the paper outlines how pharma can design activation pathways that improve patient outcomes and commercial performance. Learn how leading organizations are rethinking patient activation for Europe’s evolving healthcare landscape.
